No Data
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
TherapeuticsMD (TXMD.US): The 2024 Q1 financial report achieved revenue of US$313,000, previous value of US$416,000; earnings per share were -0.07 USD, prior value of -0.24 USD.
TherapeuticsMD (TXMD.US): The 2024 Q1 financial report achieved revenue of US$313,000, previous value of US$416,000; earnings per share were -0.07 USD, prior value of -0.24 USD.
TherapeuticsMD | 10-Q: Quarterly report
TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.07) per share. This is a 70.83 percent increase over losses of $(0.24) per share from the same period last year.
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Press Release: TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD Announces First Quarter 2024 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)--May 10, 2024-- TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company tha